Please provide your email address to receive an email when new articles are posted on . Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with ...

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...

Dear Dr. Roach: I am a 74-year-old woman who is in good health. I was diagnosed with pyoderma gangrenosum on my left leg and I was in a lot of pain. Can you tell me the cause of this rare disease?

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...

Vilobelimab is a first-in-class anti-human complement factor C5a monoclonal antibody. The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ...